In this exclusive MedPage Today video, Joel Gelfand, MD, of Penn Medicine in Philadelphia, dives into data on secukinumab and its effects on vascular inflammation in psoriasis patients, which were presented at the American Academy of Dermatology’s recent annual meeting.
The following is a transcript of his remarks:
As I’m sure most people know, people with moderate to severe psoriasis have a higher risk of having cardiovascular events and mortality over time. We think a lot of this is the relationship between psoriasis and cardiovascular disease is mediated by shared inflammatory pathways. This motivates the obvious hypothesis that perhaps treating psoriasis successfully will result in a lowering of the risk of cardiovascular disease over time.
Now, of course, to truly understand events that will change with a new therapy, that takes many years of studying to figure that out. We’re conducting a series of what’s called biomarker studies or surrogate marker studies to look at the effects our psoriasis treatments. In a randomized, placebo-controlled trial with secukinumab, we basically showed that it had no impact on aortic vascular inflammation, a measure of future cardiovascular risk in people with psoriasis, and also sort of no to minimal effects on cardiovascular biomarkers in the blood, things like inflammatory pathways, measure the liver metabolism, measure of adiposity, the measures of diabetes.
I think what we [can] conclude from this data is that the IL-17 pathway doesn’t seem to really perturb a lot of the pathways we look at in cardiovascular disease and cardiovascular risk, suggesting that, in fact, the therapies likely will be very safe for treating people who have a history of cardiovascular disease or not having any relationship with cardiovascular events in the future. That said, the largest studies wouldn’t necessarily confirm responding, and it’s certainly possible that these therapies had benefits in the cardiovascular system beyond the mechanisms that we were looking at in our study.